SCHEMBL1594429

SCHEMBL1594429

O=C(CCCl)c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 2/20 0.64
ERCC5 P28715 1/20 0.60
FEN1 P39748 1/20 0.60
POLB P06746 1/20 0.56
PARP10 Q53GL7 1/20 0.55
TDP1 Q9NUW8 2/20 0.53
LMNA P02545 1/20 0.53
MAPT P10636 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
SRD5A2 P31213 4/20 0.53
MEN1 O00255 1/20 0.52
GAA P10253 1/20 0.52
KMT2A Q03164 1/20 0.52
FFAR1 O14842 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
RNF4 P78317 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5661734 0.90 MMP1 (0.60) MMP1ERCC5FEN1POLBPARP10
SCHEMBL9814634 0.89 MMP1 (0.77) MMP1ERCC5FEN1POLBPARP10
SCHEMBL11149859 0.86 MMP1 (0.67) MMP1ERCC5FEN1TDP1MAPT
SCHEMBL19317520 0.85 MMP1 (0.68) MMP1ERCC5FEN1POLBPARP10
SCHEMBL19317521 0.85 MMP1 (0.68) MMP1ERCC5FEN1POLBPARP10
SCHEMBL1593331 0.85 GSK3B (0.67) MMP1ERCC5FEN1POLBPARP10
SCHEMBL11507093 0.84 NPC1 (0.56) MMP1ERCC5FEN1LMNAL3MBTL1
SCHEMBL19317519 0.84 L3MBTL1 (0.68) MMP1ERCC5FEN1POLBPARP10
SCHEMBL19317524 0.84 L3MBTL1 (0.68) MMP1ERCC5FEN1POLBPARP10
SCHEMBL10534992 0.84 L3MBTL1 (0.68) MMP1ERCC5FEN1POLBPARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8217001-B2 Modification of feeding behavior IMPERIAL INNOVATIONS LIMITED 2012-07-10 US disclosed
US-7919329-B2 Using proopiomelanocortin neuronal regulatory sequences to identify agents that affects caloric intake, energy expenditure, appetite or food intake; treating eating disorders and/or cachexia OREGON HEALTH & SCIENCE UNIVERSITY (US) 2011-04-05 US disclosed
US-20090209461-A1 MODIFICATION OF FEEDING BEHAVIOR IMPERIAL COLLEGE INNOVATIONS LTD. (GB) 2009-08-20 US disclosed
EP-2050460-A1 PYY and agonists thereof for modification of feeding behaviour Imperial Innovations Limited (GB) 2009-04-22 EP disclosed
US-7459432-B2 Modification of feeding behavior IMPERIAL COLLEGE INNOVATIONS LTD. (GB) 2008-12-02 US disclosed
US-20080213803-A1 ASSESSMENT OF NEURONS IN THE ARCUATE NUCLEUS TO SCREEN FOR AGENTS THAT MODIFY FEEDING BEHAVIOR OREGON HEALTH & SCIENCE UNIVERSITY 2008-09-04 US disclosed
EP-1585956-A2 ASSESSMENT OF NEURONS IN THE ARCUATE NUCLEUS TO SCREEN FOR AGENTS THAT MODIFY FEEDING BEHAVIOR Oregon Health and Science University (US) 2005-10-19 EP disclosed
EP-1499277-A4 MODIFICATION OF FEEDING BEHAVIOR IMP COLLEGE INNOVATIONS LTD (GB) 2005-08-31 EP disclosed
US-20050176630-A1 adminsteration of Peptide YY or an agonist to a overweight subject, or having obesity related disorders, results in decreased food intake, caloric intake, appetite, and an alteration in energy metabolism NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-08-11 US disclosed
EP-1499277-A2 MODIFICATION OF FEEDING BEHAVIOR Imperial College Innovations Limited (GB) 2005-01-26 EP disclosed
US-20050015820-A1 Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-01-20 US disclosed
WO-2003026591-A9 MODIFICATION OF FEEDING BEHAVIOR IMP COLLEGE INNOVATIONS LTD (GB) 2004-07-08 WO disclosed
WO-2003027637-A2 ASSESSMENT OF NEURONS IN THE ARCUATE NUCLEUS TO SCREEN FOR AGENTS THAT MODIFY FEEDING BEHAVIOR OREGON HEALTH AND SCIENCE UNIVERSITY (US) 2003-04-03 WO disclosed
WO-2003026591-A2 MODIFICATION OF FEEDING BEHAVIOR IMPERIAL COLLEGE INNOVATIONS LTD. (GB) 2003-04-03 WO disclosed
EP-1206262-A4 NPY ANTAGONISTS: SPIROISOQUINOLINONE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2003-01-02 EP disclosed
EP-1206262-A1 NPY ANTAGONISTS: SPIROISOQUINOLINONE DERIVATIVES Bristol-Myers Squibb Company (US) 2002-05-22 EP disclosed
US-6348472-B1 ANOREXIGENIC AGENTS AND EATING DISORDERS BRISTOL-MYERS SQUIBB COMPANY 2002-02-19 US disclosed
WO-2001013917-A1 NPY ANTAGONISTS: SPIROISOQUINOLINONE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2001-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176630-A1 adminsteration of Peptide YY or an agonist to a overweight subject, or having obesity related disorders, results in decreased food intake, caloric intake, appetite, and an alteration in energy metabolism NPY4R, NPY2R, NPY1R MMP1 3949/4885ERCC5 4882/4885FEN1 4866/4885
US-20090209461-A1 MODIFICATION OF FEEDING BEHAVIOR NPY4R, NPY5R, NPY2R MMP1 4336/4885ERCC5 4881/4885FEN1 4681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.